Combining cellular and gene therapy approaches for treatment of intracranial tumors

Michelle J. Hickey; Noriyuki Kasahara; Barbara M. Mueller; Carol A. Kruse

doi:10.4161/onci.25989

Combining cellular and gene therapy approaches for treatment of intracranial tumors

Michelle J. Hickey, Noriyuki Kasahara, Barbara M. Mueller, Carol A. Kruse

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T lymphocytes and replicating retroviral vectors coding for prodrug activating enzymes followed later with nontoxic prodrug demonstrated efficacy without off-target effects.

Original language	English (US)
Article number	e25989
Journal	OncoImmunology
Volume	2
Issue number	10
DOIs	https://doi.org/10.4161/onci.25989
State	Published - 2013
Externally published	Yes

Fingerprint

Keywords

alloCTL
Brain cancer
Breast cancer
Gene therapy
Immunotherapy
Metastasis
Retrovirus

ASJC Scopus subject areas

Immunology and Allergy
Oncology
Immunology

Cite this

Hickey, M. J., Kasahara, N., Mueller, B. M., & Kruse, C. A. (2013). Combining cellular and gene therapy approaches for treatment of intracranial tumors. OncoImmunology, 2(10), [e25989]. https://doi.org/10.4161/onci.25989

@article{9fa897ba6e15438d9f9ada99abdb60a9,

title = "Combining cellular and gene therapy approaches for treatment of intracranial tumors",

abstract = "New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T lymphocytes and replicating retroviral vectors coding for prodrug activating enzymes followed later with nontoxic prodrug demonstrated efficacy without off-target effects.",

keywords = "alloCTL, Brain cancer, Breast cancer, Gene therapy, Immunotherapy, Metastasis, Retrovirus",

author = "Hickey, {Michelle J.} and Noriyuki Kasahara and Mueller, {Barbara M.} and Kruse, {Carol A.}",

year = "2013",

doi = "10.4161/onci.25989",

language = "English (US)",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "10",

}

TY - JOUR

T1 - Combining cellular and gene therapy approaches for treatment of intracranial tumors

AU - Hickey, Michelle J.

AU - Kasahara, Noriyuki

AU - Mueller, Barbara M.

AU - Kruse, Carol A.

PY - 2013

Y1 - 2013

N2 - New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T lymphocytes and replicating retroviral vectors coding for prodrug activating enzymes followed later with nontoxic prodrug demonstrated efficacy without off-target effects.

AB - New treatments are needed for brain metastasis, which is associated with high morbidity and mortality. Two novel cellular and gene therapy modalities were evaluated in xenograft models for human breast cancer. The individual and especially the combined treatments with alloreactive cytotoxic T lymphocytes and replicating retroviral vectors coding for prodrug activating enzymes followed later with nontoxic prodrug demonstrated efficacy without off-target effects.

KW - alloCTL

KW - Brain cancer

KW - Breast cancer

KW - Gene therapy

KW - Immunotherapy

KW - Metastasis

KW - Retrovirus

UR - http://www.scopus.com/inward/record.url?scp=84890280183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890280183&partnerID=8YFLogxK

U2 - 10.4161/onci.25989

DO - 10.4161/onci.25989

M3 - Article

AN - SCOPUS:84890280183

VL - 2

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 10

M1 - e25989

ER -

Access to Document

10.4161/onci.25989